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Abstract
Although numerous factors have been found to modulate hTERT transcription, the mechanism of its repression in
certain leukemias remains unknown. We show here that DEK represses hTERT transcription through its enrichment
on the hTERT promoter in cells from chronic and acute myeloid leukemias, chronic lymphocytic leukemia, but not
acute lymphocytic leukemias where hTERT is overexpressed. We isolated DEK from the hTERT promoter incubated
with nuclear extracts derived from fresh acute myelogenous leukemia (AML) cells and from cells expressing Tax,
an hTERT repressor encoded by the human T cell leukemia virus type 1. In addition to the recruitment of DEK, the
displacement of two potent known hTERT transactivators from the hTERT promoter characterized both AML cells
and Tax-expressing cells. Reporter and chromatin immunoprecipitation assays permitted to map the region that
supports the repressive effect of DEK on hTERT transcription, which was proportionate to the level of DEK-promoter
association but not with the level of DEK expression. Besides hTERT repression, this context of chromatin redistribu-
tion of DEK was found to govern about 40% of overall transcriptional modifications, including those of cancer-prone
genes. In conclusion, DEK emerges as an hTERT repressor shared by various leukemia subtypes and seems involved
in the deregulation of numerous genes associated with leukemogenesis.
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Introduction
The majority of human tumor cells possess shorter telomeres than
their normal counterparts, suggesting that abnormal telomere shorten-
ing is frequently involved in cancer [1–3]. The cellular reverse tran-
scriptase telomerase counteracts telomere shortening. This enzyme is
composed of a catalytic protein subunit, telomerase reverse transcrip-
tase (hTERT ), and an RNA template (hTR). Malignant cells regularly
bypass replicative senescence and paradoxically combine high telo-
merase activity with short telomere length [1]. However, the positive
correlation between hTERT overexpression, increased telomerase ac-
tivity, and oncogenesis does not seem to be mandatory in all tumor
cases because hTERT underexpression has been shown at some stages
of chronic myeloid leukemia (CML) [4,5], adult T cell leukemia/
lymphoma [6–8], chronic lymphocytic leukemia (CLL) [9], and acute
myelogenous leukemia (AML) [10]. To date, hTERT transcriptional
repression has been considered as a tumor-suppressor pathway [11],
and in contrast to transcriptional hTERT activation, very little is
known about how hTERT is transcriptionally repressed in some
hematological malignancies.
The protein DEK was originally identified as a fusion with the
CAN/NUP214 nucleoporin in a subset of AML patients who harbored
the (6;9)(p23;q64) translocation and was subsequently found
overexpressed in most AMLs, as in numerous solid tumors [12].
DEK-CAN induces leukemia in mouse models [13], while its role of
DEK in transcription varies on the basis of cell type, gene target, and
developmental context. DEK enhances the transcription capacity of
AP-2 in human malignant glioblastoma [14] and acts as a co-activator
of the nuclear splicing factor U2AF in HeLa cells [15]. However, DEK
acts as a co-repressor on p65/nuclear factor κB [16]. More recently,
Koleva et al. showed that through their chromatin redistribution,
DEK and C/EBPα cooperate together to coordinately activate myeloid
gene expression and thereby regulate the differentiation capacity of
hematopoietic progenitors [17].
We conducted the present study to assess how hTERT is trans-
criptionally repressed in certain leukemias. We designed a magnetic
promoter precipitation assay coupled with mass spectrometry (MPP-
MS) to identify proteins bound to the hTERT promoter in various
cell types. We and others previously found that the oncoprotein
Tax encoded by the human T cell leukemia virus type 1 (HTLV-1)
represses hTERT transcription [6,7,18,19] in proliferating cells,
whereas it activates hTERT expression in quiescent cells [7,20].
We therefore hypothesized that leukemic cells with low hTERT
expression and Tax-expressing cells might share similar mechanisms
of hTERT repression. Using a Tax-based system of hTERT tran-
scriptional repression [6], we first demonstrated that Tax displaces
transactivators from the hTERT promoter, where it recruits DEK
that we subsequently characterized as an hTERT transcriptional
repressor. Furthermore, the data indicate that Tax-expressing cells
and fresh AML cells shared numerous common changes of the
hTERT promoter proteome including DEK recruitment. Given that
DEK is a chromatin protein deregulated in leukemias, we then
begun to investigate whether or not DEK was involved in the deregu-
lation of additional Tax-targeted genes as in the repression of hTERT
in HTLV-1–unrelated leukemias.
Materials and Methods
The detailed materials and methods are described in the Supplementary
Materials and Methods.
Cell Material
After consent was obtained in accordance with the Declaration of
Helsinki and institutional guidelines, bone marrow (BM) cells were
obtained from 6 donors and 20 patients (Table W1). CD34+ cells
were isolated from mononuclear cells using immunomagnetic
microbeads and the Dynal CD34 progenitor cell selection system
(Dynal Biotechnologies, Oslo, Norway). B-lymphocytes were puri-
fied by negative selection using the RosetteSep human B cell enrich-
ment cocktail (STEMCELL Technologies, Grenoble, France). HeLa
cells were obtained from the European Collection of Cell Cultures
(ECCAC, Salisbury, United Kingdom).
Plasmids, Transient Transfection, Immunoprecipitation,
and Western Blot Analysis
HeLa and Jurkat cells were transiently transfected using the calcium
phosphate precipitation method (CalPhos Transfection Kit; Clontech,
Shiga, Japan) and SuperFect reagent (Qiagen, Courtaboeuf, France),
respectively. Lipofectamine RNAi Max (Invitrogen, Carlsbad, CA)
was used as the small interfering RNA (siRNA) delivery system. The
plasmid vectors pTERTluc800, pCMV-Tax, pCMV-USF2a, and
pNGLV3-DEKwere previously described [6,21–24]. The corresponding
empty vectors were used as controls. DEK siRNA was purchased from
Dharmacon (Lafayette, CO). The co-immunoprecipitation experiments
were carried out using NP-40 incubation buffer (150mMNaCl, 50mM
Tris-HCl (pH 7.5), 1% NP-40, 50 mM N -ethylmaleimide, 2 mM
EDTA, and protease inhibitors, 1:200, P8340 Sigma, St Louis, MO)
and Protein G Sepharose Fast Flow (Sigma). Antibodies are detailed in
the Supplementary Materials and Methods.
Quantitative Chromatin Immunoprecipitation and
Quantitative Reverse Transcription–Polymerase
Chain Reaction
The isolation, sonication, and chromatin immunoprecipitation
(ChIP) analysis of nucleoprotein complexes of HeLa cells and leukemic
cells are detailed in the Supplementary Materials and Methods. Quan-
titative reverse transcription–polymerase chain reaction (qRT-PCR)
assays were performed on a LightCycler 2.0 system (Roche Applied
Science, Indianapolis, IN) using the SYBR Green qPCR SuperMix
UDG kit as detailed in the Supplementary Materials and Methods.
The expression of each gene of interest was normalized against two
housekeeping genes, Gus (NM_000181) and HPRT (NM_000194).
All controls or samples were analyzed in duplicate. Primer sequences
are provided in the Supplementary Materials and Methods.
Array Hybridization and Processing
After quality control, total RNA was amplified and biotin-labeled
by a round of in vitro transcription. It was then fragmented and
hybridized. Slides were scanned and the image files were analyzed
using CodeLink expression software. The microarray analyses con-
sisted of statistical comparison and filtering using GeneSpring software
7.3.1 (Agilent Technologies, Santa Clara, CA). See Supplementary
Materials and Methods.
Proteomic Analysis of hTERT Promoter Occupancy In Vivo
Biotinylated hTERT core promoter (hCP) was amplified by PCR
from the pTERTLuc800 plasmid [6]. The control template corre-
sponded to a PCR-generated fragment of the HTLV-1 provirus pX
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region. Streptavidin beads were incubated with biotinylated templates.
The beads/DNA complexes were washed, and immobilized templates
were freshly prepared before each experiment. Finally, reaction compo-
nents were incubated for 40 minutes at room temperature with 400 μg
of dialyzed nuclear extracts (NEs). After washing, DNA template–specific
proteinswere eluted and resolved by sodiumdodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE). See Supplementary Materials and
Methods.
Figure 1. Proteomic analysis of hTERT promoter occupancy. (A) Nuclear protein extracts were prepared either from HeLa cells transfected
with a Tax-expressing plasmid (right) or from fresh BM AML tumor cells. HeLa cells transfected with the control empty plasmid and normal
BM CD34+ cells served as controls (left). Proteins were incubated with biotin-labeled DNA probes that corresponded to the hCP or to a
control DNA stretch (BpX), as detailed in the Materials and Methods section. After SDS-PAGE fractionation, eluted products were digested
with trypsin and then analyzed by MS. (B) The Venn diagram (top) represents the distribution of proteins detected in Tax+ versus Tax− NEs
analyzed as shown in A. Data correspond to proteins recurrently detected in three independent experiments. Isolated proteins are de-
scribed in Table W2. (Bottom) Distribution of hTERT promoter partners shared between transfected HeLa cells and BM cells derived from
donors or from patients with AML.
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Nano-Liquid Chromatography Coupled to Tandem Mass
Spectrometry (LC–MS/MS) Analysis
The method consisted of a 60-minute gradient at a flow rate of
200 nl/min, using a gradient of two solvents. MS and tandem mass
spectrometry (MS/MS) data were acquired and processed auto-
matically. Consecutive searches against, first, a contaminant database
and then against the SwissProt and TREMBL databases were per-
formed for each sample. See Supplementary Materials and Methods.
Statistics
Associations between categorical variables were analyzed by Fisher
exact tests. The central tendency differences between groups were
compared with the Mann-Whitney or Kruskal-Wallis tests. Non-
parametric linear correlations between characteristics were analyzed
by the Spearman rank test. All P values were two-sided.
Results
Tax-Expressing Cells and Fresh Myeloblasts Share Common
hTERT Promoter Proteome Modifications
After validation of MPP assays as a reliable tool for isolation of specific
hTERT promoter partners (Supplementary Results and Figure W1),
our MPP-MS assays (Figure 1A) permitted to isolate 268 hCP-bound
proteins from NEs deriving from Tax− or Tax+ cells (Figure 1B and
Table W2). Of these, 22 and 18 were identified in NEs derived from
Tax− and Tax+ cells, respectively. As shown in Figure 1B (bottom) and
Table W2, myeloblast- and normal CD34+-derived NEs shared com-
mon hTERT promoter partners with Tax+- and/or Tax−-derived NEs.
Remarkably DEK, TOP1, NHPX, and RUXE were eluted from hCP
incubated with Tax+- and myeloblast- but not from Tax−- and normal
CD34+-derived NEs (Table W2). In contrast, MSH2, hnRNP D0,
and RIB1 were eluted from hCP incubated with Tax−- and CD34+-
but not from Tax+- and myeloblast-derived NEs. These similarities
suggested that, although occurring in different phenotypic contexts,
both leukemic processes, i.e., AML and adult T cell leukemia, might
share common mechanisms of hTERT repression.
hTERT Promoter Repression Coincides with the Displacement
of hTERT Transactivators and the Recruitment of DEK
To validate MS data, we assessed the hTERT promoter occupancy
in vivo for some MPP-eluted factors. Among those specifically isolated
from Tax− and normal CD34+ cells, but not from Tax+ and AML
NEs, we selected the proteins MSH2 and hnRNPD0 because they have
been previously reported to activate hTERT transcription through
binding two distinct regions on the hTERT promoter in oral squamous
cell carcinoma cells [25]. Quantitative ChIP (qChIP) assays showed
that the relative amounts of immunoprecipitated hTERT promoter
fragments were lower in Tax+ than in Tax− cells (2.2- and 1.4-fold for
hnRNPD0 and MSH2, respectively; Figure 2). Among the hCP-
bound proteins specifically shared by Tax+- and AML-hCP proteomes
(Table W2), we paid particular attention to the proto-oncogene DEK
due to its important role in modifying the chromatin topology and gene
expression during cell differentiation and transformation [26]. DEK occu-
pancy of hTERT promoter was estimated by qChIP with anti-DEK anti-
body and seven primer sets spanning the hCP (Figure 3A). Figure 3A
shows that DEK-DNA association was higher in Tax-expressing cells. In
addition, the amount of amplified DNA varied along the immuno-
precipitated hTERT promoter from Tax+ cells where the intensity peaked
at 9.46% input with the TERT6 primer set that overlaps the transcrip-
tion start site (Figure 3A). The effect of DEK on hTERT transcription was
then assessed through reporter assays. Figure 3B shows that pNGLV3-
DEK inhibited TERTLuc800 expression in a concentration-dependent
manner and that Tax expression showed an additive effect on this repres-
sion. Conversely, siRNA-mediated knockdown of DEK expression
increased hTERT transcription and abolished the negative effect of Tax
on endogenous hTERT expression in HeLa cells (Figure 3C ). Change
in DEK expression level was also found to modulate endogenous hTERT
expression in Jurkat cell lines (not shown).
In Fresh Leukemic Cells, DEK Recruitment Parallels
hTERT Transcriptional Repression
The above results prompted us to investigate whether the DEK-
mediated transcriptional repression of hTERT pertains to other leuke-
mic contexts. To this end, hTERT transcripts were quantified by qPCR
in cells derived from CML, acute lymphoblastic leukemia (ALL), and
CLL patients (Table W1) and in normal BM mononuclear cells
(BMMNCs) and purified B cells used as controls. In parallel, the fold
enrichment of DEK at the hTERT promoter DNA sequences was
assessed by qChIP assays in the same samples (Figure 4). The mean
amounts of hTERT transcripts for AML, CML, ALL, and CLL values
were 0.28, 0.41, 0.98, and 0.26 arbitrary units, respectively, while those
Figure 2. hnRNP D0 and MSH2 are displaced from the hTERT pro-
moter upon Tax expression. Analysis of MSH2 (A) and hnRNP D0
(B) associations with the hTERT promoter was carried out by qChIP
with HeLa cells expressing or not Tax, using antibodies against
hnRNP D0 and MSH2 and qPCR with PCR primers complementary
to the hTERT promoter, as described in the Materials and Methods
section. qChIP assays were performed in triplicates with P < .05
(*) tested with the one-tailed Mann-Whitney test.
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of normal BMMNCs, purifiedBMCD34+ cells, and purified peripheral
B cells were 0.76, 0.73, and 0.72 arbitrary units, respectively. This con-
firmed previous results showing that hTERT expression is increased in
ALL and decreased in CML, CLL, and AML [4–7,9,10,19]. The
mean fold enrichment of DEK at the hTERT promoters in normal
BMMNCs, normal BM purified CD34+ cells, AML, CML, ALL,
normal purified circulating B cells, and CLL samples were 0.44, 0.56,
1.41, 1.74, 0.72, 0.68, and 1.76, respectively (P = .014, Kruskal-Wallis
test). Samples with the highest DEK-hTERT association displayed
the lowest amounts of hTERT transcripts, and by linear regression
analysis, a significant negative correlation linked these two values
(Figure 4A; P = .00002, R ∼ −0.75, Spearman rank correlation). In
contrast, Figure 4B shows that in vivo, DEK mRNA levels were widely
dispersed over cell samples without any statistical correlation between
DEK and hTERT mRNA levels (P = .26, R ∼ −0.21, Spearman rank
correlation). Similarly, DEK expression remained unchanged upon Tax
expression (Figure 4C ).
hTERT Repression Is Influenced by DEK
Posttranslational Modification
Both phosphorylation and acetylation decrease DEK’s DNA
affinity [16] and thereby modulate its transcriptional effects [27]. To
address the function of DEK phosphorylation on hTERT expression,
we generated a DEK phosphorylation mutant, 4ADEK, by introduc-
ing alanine substitutions at serines 301, 303, 306, and 307. These
residues were chosen because they are involved in DEK-DNA binding
[28,29]. After transfection, the overall DEK amounts were unchanged
between assays using either 4ADEK- or the wild-type (WT)–DEK-
expressing vectors (not shown). In contrast, the suppressive effect of
the 4ADEKmutant on the hTERT transcription was three times higher
than that of WT-DEK (Figure 5A). In parallel, qChIP revealed that the
4ADEK-hTERT DNA association was higher than that obtained with
the WT-DEK plasmid (Figure 5B). These results strongly supported
that DEK-DNA association governed DEK-dependent hTERT tran-
scriptional repression and suggested that DEK phosphorylation was
critical for these processes. To investigate the relationship between
DEK acetylation and hTERT expression, we assessed the amount of
acetylated DEK in Tax− and Tax+ NEs. Figure 5C shows that Tax
Figure 3. DEK binds to and suppresses the hTERT promoter on
Tax expression. (A) DEK and hTERT promoter association in Tax-
expressing cells. The seven primer pairs used for ChIP and qChIP
spanned a 964-bp region of the hTERT promoter. This region en-
compasses several known critical sites involved in the regulation of
hTERT transcription, including the transcription initiation site, the start
codon, as well as GC and E boxes. The black boxes represent the
E boxes, while the gray boxes represent the five Sp1 binding sites.
+1 is the transcription initiation site. qChIP analysis of DEK associa-
tion with the hTERT promoter was carried out as described in the
Materials and Methods section. Results (means ± SDs) are repre-
sentative of triplicate experiments. *P < .05, Mann-Whitney test. (B)
HeLa cells were co-transfected with WT hTERT promoter–luciferase
reporter plasmid TERTLuc800, in combination with the pCMV-Tax
plasmid and/or a control vector (pCMV) in the absence or presence
of increasing amounts of pNGLV3-DEK. Forty-eight hours after trans-
fection, HeLa cells were collected and transcriptional activity was
assayed by luciferase activity (see Materials and Methods section).
(Bottom) DEK and Tax expression in transfected HeLa cells were
assayed by Western blot analysis. (C) DEK knockdown increased
endogenous hTERT expression and prevented its repression by Tax.
hTERT expression was quantified through quantitative real-time PCR
in HeLa cells transfected with the pCMV-Tax plasmid and/or control
vector and/or the DEK siRNA (50 nM) and/or scrambled RNA. siRNA-
mediated knockdown of DEK expression was checked by Western
blot analysis (top). Data shown in B and C are the means (±SDs) of
one representative experiment performed in triplicate.
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Figure 4. In vivo and ex vivo, DEK recruitment on the endogenous
hTERT promoter correlates with hTERT transcriptional repression
but not with DEK expression. (A) Analysis of DEK association with
the hTERT promoter was carried out by qChIP using an antibody
against DEK and qPCR with the TERT6 primer pair as described
in the Materials and Methods section. For each sample, hTERT
expression was measured by qRT-PCR. AML, CML, and ALL cells
and BMMNCs were derived from the BM, while purified B cells and
malignant CLL cells were derived from the blood. All patient sam-
ples were collected at the time of diagnosis, after written informed
consent. Signals were normalized to input, and background levels
in immunoprecipitation (IP) with control IgGs were assigned. (B)
DEK expression did not correlate with hTERT transcriptional repres-
sion in hematological samples. For each sample, DEK and hTERT
mRNAwere quantified by qRT-PCR. (C) Tax expression did not mod-
ify DEK expression. NEs and cytoplasmic extracts from Tax- versus
control empty vector–transfected HeLa cells were analyzed by
Western blot analysis with an anti-DEK antibody.
Figure 5. Transcriptional repression of hTERT depend on posttransla-
tionalmodifications ofDEK. (A)Mutations of theDEKphosphorylation
site increase the repressive effect of DEK and Tax on hTERT promoter
activity. HeLa cells were co-transfectedwith theWT hTERT promoter–
luciferase reporter plasmid TERTLuc800, in combination with either
the pCMV-Tax plasmid, the pNGLV3-DEKWT, or the pNGLV3-4ADEK
mutant. Transcriptional activity was assayed by luciferase activity
(see Materials and Methods section). (B) Mutations of the DEK phos-
phorylation site increased the recruitment of DEK on the hTERT pro-
moter. qChIP was carried out with an anti-DEK antibody and the
TERT6 primer pair, and nuclear proteins were derived fromHeLa cells
co-transfected with either the pCMV-Tax plasmid, the pCMV control
vector, the pNGLV3-DEK WT, or the pNGLV3-4ADEK mutant. (C) Tax
decreased DEK acetylation in a TSA-independent manner. HeLa cells
were transfected with Tax or the control empty pCMV plasmid in
the presence of TSA or DMSO and subjected to immunoprecipita-
tion and Western blot analysis for DEK. The Western blot analysis
membrane was stripped and reprobed with an anti-acetylated lysine
antibody. The endogenous expression of hTERT was measured by
qRT-PCR. Error bars represent the S.D. in triplicate experiments.
Data shown in B and C are the means (±SDs) of one representative
experiment performed in triplicate. *P < .05, Mann-Whitney test.
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decreased DEK acetylation without modifying its expression. In con-
trast, the exposure of HeLa cells to the deacetylase inhibitor tricho-
statin A (TSA) led to a decrease in DEK occupancy at the hTERT
promoter (Figure W2), while it increased the amounts of both acety-
lated DEK and hTERT mRNA in HeLa cells expressing or not Tax
Table 1. Distribution of Gene Expression according to Tax Expression and DEK Knockdown.
Effect of DEK Knockdown Tax-Activated (%) Tax-Repressed (%) Tax-Unmodified (%)
Activation 539 (13) 2029 (44) 1991 (9)
Repression 1613 (40) 644 (14) 3235 (14)
None 1898 (47) 1895 (42) 18101 (77)
Figure 6. qChIP analysis of DEK-promoter association upon Tax expression for genes other than hTERT. (A) HeLa cells were transfected
with either pCMV-Tax or control pCMV empty vector, and qChIP was carried out with a DEK antibody and PCR primers complementary
to a promoter region encompassing the transcription start site of 19 genes. For each gene, the signal was normalized to input for Tax+ (blue)
and Tax−HeLa cells (red). As indicated at the bottom, these genes included five DEK-dependent/Tax-repressed (left), seven DEK-dependent/
Tax-activated (center), and seven DEK-independent/Tax-unmodified genes (right). For each gene category, a horizontal blue line represents
the mean DEK-promoter association ratio of Tax+ to Tax− signals. (B) Distribution of “cancer” pathways according to the DEK-dependent
(red circles) versus DEK-independent (black circles) nature of Tax-targeted genes. A blue asterisk identifies Tax-independent genes that
were deregulated on siRNA knockdown of DEK.
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(Figure 5C ). This suggests that DEK acetylation could counteract
the transcriptional repression of hTERT. Typically, modifications in
DEK acetylation could result from either Tax-induced deacetylase
activity or Tax-induced inhibition of histone acetyltransferase activity.
However, Figure 5C shows that TSA exposure did not alleviate the
negative effect of Tax on DEK acetylation (Figure 5C), thereby ruling
out the Tax-dependent deacetylation possibility. Therefore, it was
possible to propose that the decreased amount of acetylated DEK
mainly relies on a Tax-triggered histone acetyltransferase inhibition
rather than on a Tax-triggered deacetylase effect. Taken together, these
results demonstrated that DEK-dependent hTERT repression does not
rely on increased DEK expression but rather on a greater DEK-DNA
association, the level of which seems to be modulated at the post-
translational level through DEK phosphorylation and acetylation.
Tax-Associated Cellular Gene Transcriptional Deregulation
Frequently Depends on DEK
Given that DEK is an abundant chromatin protein in human cells,
we investigated whether Tax-mediated chromatin redistribution of
DEK might influence the transcription of other genes than hTERT.
As detailed in the Supplementary Results and shown in Tables 1,
W3, and W4, DEK was found involved in the transcriptional deregu-
lation of 42% of Tax-targeted genes including 44% of Tax-repressed
genes and 40% of Tax-activated genes. qChIP assays showed that
Tax expression strengthened DEK recruitment on the promoter of
12/12 genes found to be transcriptionally modified by Tax in a DEK-
dependent manner, including 5/5 Tax-repressed and 7/7 Tax-activated
genes (Figure 6A). Furthermore, qChIP revealed that the average level
of DEK-hTERT promoter association was higher for Tax-activated
(P = .0117) and Tax-repressed (P = .0088) genes than for unmodified
genes. By using the DAVID bioinformatics resources (http://david.
abcc.ncifcrf.gov/), ontological analysis of the Tax-targeted genes
showed that the two top-ranked term categories “Pathways in cancer”
and “Cytokine-cytokine receptor interaction” were DEK-dependent
(Supplementary Results, Tables 1, 2, and W4). In contrast, the terms
“Neuroactive ligand-receptor interaction” and “MAPK signaling
pathway” appeared independent of DEK. Figure 6B represents the
“Pathways in cancer” and shows that the vast majority of Tax-targeted
genes in these pathways are DEK-dependent genes.
Discussion
The study identified and characterized hTERT promoter partners
involved in hTERT transcriptional repression in leukemias. Some of
these partners such as MSH2 and hnRNP D0 were found displaced
from the hTERT promoter in both AML cells and Tax-expressing
cells, while other factors including DEK were found recruited to this
promoter in both cell subtypes. Given its known implication in leu-
kemias, we further detailed the role of DEK in hTERT transcription.
DEK was found recruited on hTERT promoter not only in AML and
Tax-expressing cells but also in CML and CLL cells. We found that
DEK repressed hTERT transcription and that this repression relied
on the recruitment of DEK on the hTERT promoter but not on the
amounts of DEK protein in tumoral cells. Posttranslational DEK
modifications were found to influence its interplays with hTERT. In
addition to hTERT, DEK/promoter enrichment was also found to
regulate more than 40% of Tax-controlled genes, including those
having critical roles in cancer.
DEK has emerged as a novel class of DNA topology modulators that
can be both targets and effectors of tumor initiation and addiction
[12,16]. The proto-oncogene DEK is involved in chromatin remodel-
ing, transcriptional repression or activation, and mRNA maturation
[12,16]. DEK is capable to associate with numerous promoters for
modulating their occupancy in transcriptional factors and chromatin
modifiers such as hDaxx [30], P/CAF, p300, and p65/nuclear factor
κB [26,31]. DEK prefers structured DNA, such as supercoiled and
four-way junctions, to specific nucleic acid sequence [28]. Such struc-
tured DNA forms are enriched in the vicinity of promoter regions [32].
DEK and other cruciform-binding proteins such as p53, BRCA1,
MSH2, PARP1, 14-3-3, and topoisomerase 1 are frequently involved
in transcriptional regulation as well as in DNA repair and replication
[33]. Interestingly, our results show that in addition to enrichment
in the cruciform-binding protein DEK at the vicinity of the hTERT
transcription start site, hTERT repression also included changes in
occupancy of additional cruciform-binding proteins such as MSH2,
hnRNPs, and topoisomerase 1 (Figure 1).
AML, CML, and CLL cells display significantly lower amounts
of hTERT transcripts than their normal counterparts [4,5,9,10]. In
contrast, ALL cells overexpress hTERT when compared to normal
BMMNCs or to normal B or T lymphocytes [10,34]. These results
were confirmed in the present series of 20 additional patients (Figure 5),
where there was no significant difference in the level of DEK expres-
sion between AML, ALL, CML, CLL, and normal BM samples or
normal B cells. In contrast, qChIP revealed a significantly higher
DEK-hTERT promoter association in AML, CML, and CLL than in
control cells (Figure 4). In ALL cells, which express elevated amounts
of hTERT mRNA, the hTERT promoter was found depleted of DEK.
A strong negative correlation linked DEK-hTERT promoter associa-
tion and hTERT expression supporting an identical interplay between
DEK-hTERT promoter association and hTERT expression in fresh
leukemic cells and Tax-expressing cells. Knowing now that Tax re-
presses hTERT in a concentration-dependent manner [6] through
Table 2. Ontological Analysis of DEK-Dependent and DEK-Independent Tax-Targeted Genes.
Terms Gene Count P
Enriched Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways of genes dysregulated
by Tax expression in a DEK-dependent or
DEK-independent manner
hsa04080: neuroactive ligand-receptor interaction 63 9.193E−06
hsa04010: MAPK signaling pathway 59 4.504E−04
hsa05200: pathways in cancer 59 4.257E−02
hsa04060: cytokine-cytokine receptor interaction 52 1.052E−02
hsa04020: calcium signaling pathway 48 7.685E−06
hsa04514: cell adhesion molecules (CAMs) 26 7.960E−02
hsa04270: vascular smooth muscle contraction 25 2.403E−02
hsa05416: viral myocarditis 19 9.047E−03
hsa05414: dilated cardiomyopathy 19 9.702E−02
hsa05412: arrhythmogenic right ventricular
cardiomyopathy (ARVC)
18 3.614E−02
hsa05410: hypertrophic cardiomyopathy (HCM) 18 8.922E−02
hsa04730: long-term depression 17 3.043E−02
hsa05218: melanoma 17 3.881E−02
hsa04260: cardiac muscle contraction 17 8.103E−02
hsa02010: ABC transporters 11 8.656E−02
Enriched KEGG pathways of genes dysregulated by
Tax expression in a DEK-independent manner
hsa04080: neuroactive ligand-receptor interaction 34 1.833E−04
hsa04010: MAPK signaling pathway 26 5.523E−02
hsa04020: calcium signaling pathway 23 3.228E−03
hsa04514: cell adhesion molecules (CAMs) 15 5.862E−02
hsa04340: hedgehog signaling pathway 9 3.217E−02
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the parallel recruitment of DEK on the hTERT promoter (present
results), it could be speculated that, in AML, CML, and CLL cells, a
Tax surrogate that reproduces the same telomere effects as those
observed in Tax-expressing cells exists. Accordingly, deciphering the
DEK interactome in leukemic cells will help identify the important
factors involved in telomere-dependent chromosomal instability. Given
that DEK is overexpressed in numerous tumor types, the effects of
DEK on gene expression, cell differentiation, and transformation have
hitherto mainly been studied through DEK overexpression and/or
genetic depletion. Here, DEK was found to repress hTERT ex vivo in
a concentration-dependent manner. However, in Tax+ cells as in AML,
CML, and CLL cells, our results did not support any correlation be-
tween the cellular amounts of DEK and the expression level of its
target genes. Rather, our study pinpoints DEK redistribution along the
chromatin as the main process governing its target gene transcription.
Consistent with the known relationships between DEK acetylation or
phosphorylation and its DNA affinity [16], the present results strongly
suggest that through influencing DEK-DNA affinity and thereby target
gene expression, qualitative and quantitative posttranslational changes
of the DEK protein play an important role in tumorigenesis.
In conclusion, DEK was found here to repress hTERT through its
redistribution on the hTERT promoter, thus permitting to explain the
recently shown suboptimal hTERT expression in CLL [9], CML [4,5],
and AML [10,34] as in certain Tax-expressing cells, such as activated
HTLV-1–positive but untransformed CD4+ T cells [8]. Preventing
telomere elongation in proliferating premalignant cells is assumed to
promote genetic instability leading to tumor initiation. In overt trans-
formed cells, such telomere defects are assumed to sustain genetic plas-
ticity, permitting immune escape, resistance to treatment, and relapse.
DEK redistribution appears to be involved in more than 40% of Tax-
targeted genes and helps explain the transcriptional pleiotropic effect of
Tax, notably in the field of oncogenesis (Table 2 and Figure 6B).Whether
DEK redistribution leads to such pleiotropic transcriptional effects in
other HTLV-1–unrelated leukemias remains to be investigated.
Acknowledgments
We thank W.C. Greene for the pCMV-Tax plasmid, B. Viollet for the
pCR3-USF2a plasmid and anti-USF antibodies, and D.M. Markovitz
for the pNGLV3-DEK plasmid. The authors thank the genomic plat-
form facility ProfileXpert (Université Lyon I, Bron, France) and the
PLATIM (Plateau Technique Imagerie/Microscopie, Université Lyon I,
Lyon France) for microarray and microscopy analyses, respectively.
References
[1] Deng Y, Chan SS, and Chang S (2008). Telomere dysfunction and tumour
suppression: the senescence connection. Nat Rev Cancer 8, 450–458.
[2] Christodoulidou A, Raftopoulou C, Chiourea M, Papaioannou GK, Hoshiyama
H, Wright WE, Shay JW, and Gagos S (2013). The roles of telomerase in the
generation of polyploidy during neoplastic cell growth. Neoplasia 15, 156–168.
[3] Kuzyk A and Mai S (2012). Selected telomere length changes and aberrant
three-dimensional nuclear telomere organization during fast-onset mouse plasma-
cytomas. Neoplasia 14, 344–351.
[4] Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ,
Wainscoat JS, and Boultwood J (2006). hTERT, the catalytic component of
telomerase, is downregulated in the haematopoietic stem cells of patients with
chronic myeloid leukaemia. Leukemia 20, 671–679.
[5] Drummond MW, Hoare SF, Monaghan A, Graham SM, Alcorn MJ, Keith
WN, and Holyoake TL (2005). Dysregulated expression of the major telomerase
components in leukaemic stem cells. Leukemia 19, 381–389.
[6] Gabet AS, Mortreux F, Charneau P, Riou P, Duc-Dodon M, Wu Y, Jeang KT,
and Wattel E (2003). Inactivation of hTERT transcription by Tax. Oncogene
22, 3734–3741.
[7] Hara T, Matsumura-Arioka Y, Ohtani K, and Nakamura M (2008). Role of
human T-cell leukemia virus type I Tax in expression of the human telomerase
reverse transcriptase (hTERT) gene in human T-cells. Cancer Sci 99, 1155–1163.
[8] Zane L, Sibon D, Capraro V, Galia P, Karam M, Delfau-Larue MH, Gilson E,
Gessain A, Gout O, Hermine O, et al. (2011). HTLV-1 positive and negative T
cells cloned from infected individuals display telomerase and telomere genes
deregulation that predominate in activated but untransformed CD4+ T cells.
Int J Cancer 131, 821–833.
[9] Poncet D, Belleville A, t’kint de Roodenbeke C, Roborel de Climens A,
Ben Simon E, Merle-Beral H, Callet-Bauchu E, Salles G, Sabatier L, Delic J,
et al. (2008). Changes in the expression of telomere maintenance genes suggest
global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 111,
2388–2391.
[10] Capraro V, Zane L, Poncet D, Perol D, Galia P, Preudhomme C, Bonnefoy-
Berard N, Gilson E, Thomas X, El-Hamri M, et al. (2011). Telomere deregulations
possess cytogenetic, phenotype, and prognostic specificities in acute leukemias.
Exp Hematol 39, 195–202 e192.
[11] Lin SY and Elledge SJ (2003). Multiple tumor suppressor pathways negatively
regulate telomerase. Cell 113, 881–889.
[12] Waldmann T, Scholten I, Kappes F, Hu HG, and Knippers R (2004). The
DEK protein—an abundant and ubiquitous constituent of mammalian chromatin.
Gene 343, 1–9.
[13] Oancea C, Rüster B, Henschler R, Puccetti E, and Ruthardt M (2010). The
t(6;9) associated DEK/CAN fusion protein targets a population of long-term
repopulating hematopoietic stem cells for leukemogenic transformation. Leukemia
24, 1910–1919.
[14] Campillos M, García MA, Valdivieso F, and Vázquez J (2003). Transcriptional
activation by AP-2α is modulated by the oncogene DEK. Nucleic Acids Res 31,
1571–1575.
[15] Soares LM, Zanier K, Mackereth C, Sattler M, and Valcárcel J (2006). Intron
removal requires proofreading of U2AF/3′ splice site recognition by DEK. Science
312, 1961–1965.
[16] Riveiro-Falkenbach E and Soengas MS (2010). Control of tumorigenesis and
chemoresistance by the DEK oncogene. Clin Cancer Res 16, 2932–2938.
[17] Koleva RI, Ficarro SB, Radomska HS, Carrasco-Alfonso MJ, Alberta JA, Webber
JT, Luckey CJ, Marcucci G, Tenen DG, and Marto JA (2012). C/EBPα and
DEK coordinately regulate myeloid differentiation. Blood 119, 4878–4888.
[18] Kuhlmann AS, Villaudy J, Gazzolo L, Castellazzi M, Mesnard JM, and
Duc Dodon M (2007). HTLV-1 HBZ cooperates with JunD to enhance tran-
scription of the human telomerase reverse transcriptase gene (hTERT). Retro-
virology 4, 92.
[19] Terme JM, Mocquet V, Kuhlmann AS, Zane L, Mortreux F, Wattel E, Duc
Dodon M, and Jalinot P (2009). Inhibition of the hTERT promoter by the
proto-oncogenic protein TAL1. Leukemia 23, 2081–2089.
[20] Sinha-Datta U, Horikawa I, Michishita E, Datta A, Sigler-Nicot JC, Brown M,
Kazanji M, Barrett JC, and Nicot C (2004). Transcriptional activation of
hTERT through the NF-κB pathway in HTLV-I–transformed cells. Blood 104,
2523–2531.
[21] Hausmann S, Biddison WE, Smith KJ, Ding YH, Garboczi DN, Utz U, Wiley
DC, and Wucherpfennig KW (1999). Peptide recognition by two HLA-A2/
Tax11–19-specific T cell clones in relationship to their MHC/peptide/TCR crystal
structures. J Immunol 162, 5389–5397.
[22] Cleary J, Sitwala KV, Khodadoust MS, Kwok RP, Mor-Vaknin N, Cebrat M,
Cole PA, and Markovitz DM (2005). p300/CBP-associated factor drives DEK
into interchromatin granule clusters. J Biol Chem 280, 31760–31767.
[23] Smith MJ, Charron-Prochownik DC, and Prochownik EV (1990). The leucine
zipper of c-Myc is required for full inhibition of erythroleukemia differentiation.
Mol Cell Biol 10, 5333–5339.
[24] Viollet B, Lefrancois-Martinez AM, Henrion A, Kahn A, Raymondjean M, and
Martinez A (1996). Immunochemical characterization and transacting properties
of upstream stimulatory factor isoforms. J Biol Chem 271, 1405–1415.
[25] Kang X, Chen W, Kim RH, Kang MK, and Park NH (2009). Regulation of
the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in
human oral squamous cell carcinoma cells. Oncogene 28, 565–574.
[26] Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G, and Ashburner BP
(2006). Negative regulation of the RelA/p65 transactivation function by the
product of the DEK proto-oncogene. J Biol Chem 281, 26802–26812.
Neoplasia Vol. 16, No. 1, 2014 DEK Represses hTERT in Leukemias Karam et al. 29
[27] Kappes F, Damoc C, Knippers R, Przybylski M, Pinna LA, and Gruss C
(2004). Phosphorylation by protein kinase CK2 changes the DNA binding
properties of the human chromatin protein DEK.Mol Cell Biol 24, 6011–6020.
[28] Waldmann T, BaackM, Richter N, and Gruss C (2003). Structure-specific binding
of the proto-oncogene protein DEK to DNA. Nucleic Acids Res 31, 7003–7010.
[29] Waldmann T, Eckerich C, Baack M, and Gruss C (2002). The ubiquitous
chromatin protein DEK alters the structure of DNA by introducing positive
supercoils. J Biol Chem 277, 24988–24994.
[30] Hollenbach AD, McPherson CJ, Mientjes EJ, Iyengar R, and Grosveld G
(2002). Daxx and histone deacetylase II associate with chromatin through an
interaction with core histones and the chromatin-associated protein Dek. J Cell
Sci 115, 3319–3330.
[31] Ko SI, Lee IS, Kim JY, Kim SM, Kim DW, Lee KS, Woo KM, Baek JH, Choo
JK, and Seo SB (2006). Regulation of histone acetyltransferase activity of p300
and PCAF by proto-oncogene protein DEK. FEBS Lett 580, 3217–3222.
[32] van Holde K and Zlatanova J (1994). Unusual DNA structures, chromatin and
transcription. Bioessays 16, 59–68.
[33] Brazda V, Laister RC, Jagelská EB, and Arrowsmith C (2011). Cruciform struc-
tures are a common DNA feature important for regulating biological processes.
BMC Mol Biol 12, 33.
[34] Cogulu O, Kosova B, Gunduz C, Karaca E, Aksoylar S, Erbay A, Karapinar D,
Vergin C, Vural F, Tombuloglu M, et al. (2008). The evaluation of hTERT
mRNA expression in acute leukemia children and 2 years follow-up of 40 cases.
Int J Hematol 87, 276–283.
30 DEK Represses hTERT in Leukemias Karam et al. Neoplasia Vol. 16, No. 1, 2014
Supplementary Materials and Methods
Samples Studied
After consent was obtained in accordance with the Declaration of
Helsinki and institutional guidelines, BM cells were obtained from
6 donors and 20 patients (at the Edouard Herriot University Hospital,
Lyon, France) with acute leukemias (ALs) and having more than 85%
BM blasts. BM samples were obtained from patients before treatment.
The diagnosis of leukemia was based on routine morphologic evaluation,
immunophenotyping, cytochemical smears, and karyotyping. Mono-
nuclear cell fractions from donor BM were separated using a Ficoll-
Hypaque gradient. CD34+ cells were then isolated with immunomagnetic
microbeads and the Dynal CD34 progenitor cell selection system (Dynal
Biotechnologies), according to the manufacturer’s instructions. The kits
contain Dynabeads and DETACHaBEAD for isolation and release of
pure CD34+ cells with an intact antigen profile. Purity was controlled
by FACS with CD34+–fluorescein isothiocyanate antibody (Dako,
Trappes, France).
Isolation of Normal Peripheral B Cells
B lymphocytes were purified by negative selection using the
RosetteSep human B cell enrichment cocktail (STEMCELL Tech-
nologies). The percentage of CD19+ cells was determined by cytometric
assay, using an α-CD19–phycoerythrin (PE) antibody (Amersham-
Biosciences, Uppsala, Sweden).
Plasmids and siRNA
The hTERT promoter–Luc reporter plasmid, pTERTluc800,
contains the proximal 800 bp of the hTERT promoter placed
upstream of the firefly luciferase coding region [1,2]. The Renilla
luciferase reporter construct, pHRG-TK, used as an internal control
in the luciferase-based reporter gene assays, was purchased from
Promega (Madison, WI). Expression vectors pCMV-Tax, pCMV-
USF2a, and pNGLV3-DEK plasmids were previously described [3-
5]. The corresponding empty vectors were used as controls. DEK
siRNA oligonucleotides (M-003881-01) and their respective non-
targeting siRNA (D-001210-04) were purchased from Dharmacon.
Antibodies
Antibodies to DEK were purchased either from Santa Cruz Bio-
technology (Santa Cruz, CA; H-300) or BD Biosciences (San Jose,
CA; 610948). Antibodies to MSH2 (clone 3A2) and hnRNP D0
(#07-260) were purchased from Cell Signaling Technology (Danvers,
MA) and Upstate Biotechnology (Charlottesville, VA), respectively.
The anti-Tax monoclonal antibody was HY474 [1]. The mouse mono-
clonal anti-acetylated lysine antibody was AKL5C1 from Santa Cruz
Biotechnology, while the monoclonal anti-actin (AC-40 or AC-15)
antibody was obtained from Sigma. Rabbit polyclonal antibodies rec-
ognizing USFs, USF1 and USF2a, were previously described [5]. Anti-
rabbit and anti-mouse IgG-peroxidase antibodies were used for Western
blot analysis. The antibodies used in immunofluorescence staining
experiments were goat anti-rabbit IgG2a conjugated to fluorescein
isothiocyanate and goat anti-mouse IgG conjugated to Alexa Fluor 546.
Cells, Transfections, and Reporter Assays
HeLa cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum (Invitrogen), penicillin
(100 units/ml), and streptomycin (100 μg/ml) at 37°C in a 5% CO2
incubator. Jurkat cells were grown in RPMI 1640. The calcium phos-
phate precipitation method (CalPhos Transfection Kit; Clontech)
was used for transfecting HeLa cells with expression plasmids, while
Lipofectamine RNAi Max (Invitrogen) was used as the siRNA delivery
system. For luciferase assays, cells were seeded in 24-well plates at
75% confluence and co-transfected with 500 ng of pTERTLuc800,
20 ng of the internal control Renilla luciferase reporter construct
pHRG-TK, and the indicated recombinant plasmids. Cells were
washed three times with ice-cold phosphate-buffered saline (PBS)
and harvested to analyze luciferase activity 48 hours after transfection
using a luminometer and adding a luciferase assay reagent (Promega).
Jurkat cells were transfected using SuperFect (Qiagen), according to the
manufacturer’s protocol. Data are presented as means ± SD. Data
shown in Figures 3, A–C , and 5, B, D, E , and G , are the means
(±SDs) of one representative experiment performed in triplicate.
Co-Immunoprecipitation Experiments
Whole-cell extracts were prepared from about 5 × 105 HeLa cells
transfected with either pCMV-Tax or the corresponding empty vector.
Twenty-four hours after transfection, cells were washed once with
PBS, lysed in 300 μl of NP-40 incubation buffer [150 mM NaCl,
50 mM Tris-HCl (pH 7.5), 1% NP-40, 50 mM N -ethylmaleimide,
2 mM EDTA, and protease inhibitors, 1:200, P8340; Sigma], and
clarified by centrifugation at 15,000g for 10 minutes. Proteins from
cell lysates were incubated with DEK antibody and 50 μl of Protein G
Sepharose Fast Flow (Sigma) overnight at 4°C in incubation buffer.
Beads were collected by centrifugation, washed once in NP-40 incu-
bation buffer and twice in PBS, and resuspended in Laemmli sample
buffer for Western blot analysis.
Western Blot
Cells were lysed and protein concentration was assayed using the Bio-
Rad DC Protein Assay Kit (Bio-Rad, Hercules, CA). Equal amounts of
proteins were subjected to 10% SDS-PAGE. Fractionated proteins were
transferred to polyvinylidene fluoride (PVDF)membranes (Immobilon-P
Transfer Membranes; Millipore, Billerica, MA). Membranes were
blocked in PBS containing 5% nonfat milk and 0.2% Tween 20, then
probed with the appropriate antibody, followed by secondary IgG HRP-
linked antibody (Cell Signaling Technology). Blots were then developed
using an enhanced chemiluminescence detection system (Lumi-Lightplus
Western Blotting Substrate; Roche).
Quantitative Reverse Transcription–Polymerase
Chain Reaction
RNA was isolated with TRIzol reagent (Invitrogen). Before RT,
RNA was treated with DNase (Invitrogen) to prevent DNA con-
tamination. First-strand cDNA was synthesized from 0.5 μg of RNA
using random primers (Promega) and Superscript II reverse transcrip-
tase (Invitrogen). RNA concentration and purity were determined
by UV spectrophotometry (Nanodrop, Montchanin, DE). Sequences
of primers are available on request. Each primer set used to quantify
gene expression was first tested by PCR using a control cDNA to ensure
specific amplification, as shown by the presence of a unique specific
signal after agarose gel electrophoresis (not shown). PCR assays
were performed on a LightCycler 2.0 system (Roche Applied Science).
All reactions were performed using a Platinum SYBR Green qPCR
SuperMix UDG kit. The reaction mixture contained 5 μl of water,
10 μl of SYBR GreenMaster Mix, 1 μl of BSA (20×), 2 μl of primers at
10 μM, and 2 μl of a 1/10 dilution of cDNA. The final reaction volume
was 20 μl. Water was used as a negative control. All samples were
kept at 4°C during preparation. Thermocycling conditions were as
previously described [6]. All controls or samples were analyzed in
duplicate. All fluorescence data were analyzed by LightCycler 4.0
software (Roche) and the C t results were exported to Excel sheets.
Amplified DNA with primer sets used to quantify gene expression
was diluted and aliquoted. The 10−7 dilution served as the calibrator
for all the qPCR runs. For relative quantification and normalization,
the comparative C t (or E−ΔΔC , where E was the primer-dependent
efficiency of the PCR) method was used [7]. The expression of each
gene of interest was normalized against two housekeeping genes, Gus
(NM_000181) and HPRT (NM_000194), which had been validated
with BestKeeper software tool to adjust for variations in RNA levels and
cDNA synthesis.
Quantitative Chromatin Immunoprecipitation
HeLa cells were fixed in 1% formaldehyde for 10 minutes at room
temperature and then for 40 minutes at +4°C. Cross-linking was
stopped by adding 125 mM glycine for 5 minutes. Cells were washed
in hypotonic buffer and resuspended in 1 to 2 ml of SDS lysis buffer
(1% SDS, 10 mM EDTA, and 50 mM Tris-HCl, pH 8). Nucleo-
protein complexes derived from HeLa cells expressing Tax or not
were sonicated to reduce the length of DNA fragments to 200 to
300 bp. For nucleoprotein complexes derived from patients and
donors, DNA fragments ranging from 300 to 1000 bp were obtained
after sonication. Insoluble material was removed and the supernatant
was collected. Thirty microliters of this fraction were preserved as an
input control, and the rest was diluted 1:10 in ChIP dilution buffer
(ChIP Assay Kit; Upstate Biotechnology). The chromatin solution
was precleared for 1 hour by incubation with 80 μl of salmon sperm
DNA–protein A–agarose beads (Upstate Biotechnology). The soluble
fraction was collected and 15 μl of anti-DEK and anti-mouse IgG
(Dakocytomation, Trappes, France) antibodies were added and incu-
bated overnight. Then, for ChIP monoclonal antibodies, 1 μg of rab-
bit polyclonal anti-mouse antibody (Dakocytomation) was added and
incubated for 1 hour. After immunoprecipitation, immune complexes
were collected by adding 60 μl of salmon sperm DNA–protein A–
agarose beads for 1 hour. The supernatant corresponding to the
unbound fraction was collected. After washing (according to the
manufacturer’s instructions), complexes were eluted from the beads
in 1% SDS and 0.1 M NaHCO3. This fraction corresponded to
the bound (anti-DEK) or the non–DEK-specific antibody (anti-mouse
IgG) fractions. Cross-links were reversed by heating samples at 65°C in
200 mMNaCl. DNA was recovered by proteinase K digestion, phenol
extraction, and ethanol precipitation. Finally, DNA samples from the
input, unbound, non–DEK-specific antibody, and bound fractions
were quantified by real-time PCR with specific promoter primers.
Array Hybridization and Processing
HeLa cells were transfected with either pCMV-Tax or an empty
vector. At 24-hour post-transfection, Tax-positive cells received either
scrambled siRNA or DEK siRNA, while Tax-negative HeLa cells were
transfected with a scrambled siRNA as a control. Cells were harvested
24 hours later, and Tax expression and DEK knockdown were con-
firmed by Western blot analysis of whole-cell extracts. Total RNA
was extracted using an RNeasy Mini Kit (Qiagen), including DNAse
treatment, and according to the manufacturer’s instructions. Total
RNA yield was measured by OD260, with an A260/A280 ratio of
1.9 to 2.1 demonstrating purity. Quality was evaluated on nanochips
with the Agilent 2100 Bioanalyzer (Agilent Technologies), according
to the manufacturer’s protocol. Total RNA (1 μg) was amplified and
biotin-labeled by a round of in vitro transcription with theMessageAmp
II aRNA Amplification Kit (Ambion, Huntingdon, United Kingdom),
following the manufacturer’s protocol. Before amplification, spikes of
synthetic mRNA at different concentrations were added to all samples;
these positive controls were used to ascertain the quality of the process.
The aRNA yieldwasmeasured with aNanodrop and quality checked on
nanochips with the Agilent 2100 Bioanalyzer (Agilent Technologies).
Biotin-labeled aRNA was fragmented and hybridized following
the manufacturer’s protocol (Applied Microarrays, Branchburg, NJ).
Briefly, 10 μg of aRNA was fragmented using fragmentation buffer,
then mixed with hybridization solution (Applied Microarrays), and
injected onto CodeLink HumanWhole Genome bioarrays. After over-
night hybridization at 37°C, arrays were washed and stained with a
streptavidin-cy5 solution (GE Healthcare, Freiburg, Germany). Slides
were scanned using a Genepix 4000B scanner (Axon, Union City,
CA) andGenepix software, with the laser set at 635mm, the laser power
at 100%, and the photomultiplier tube voltage at 60%. The scanned
image files were analyzed using CodeLink expression software, ver-
sion 5.0 (GE Healthcare), which produces both raw and normalized
hybridization signals for each spot on the array. The microarray analyses
consisted of statistical comparison and filtering, using GeneSpring
software 7.3.1 (Agilent Technologies). Pairwise comparisons were
performed between each cell category (Tax−, Tax+, and Tax+DEK−).
Only genes showing a fold variation of ≥1.3 were retained.
Proteomic Analysis of hTERT Promoter Occupancy In Vivo
hTERT promoter occupancy was investigated in HeLa cells express-
ing or not Tax (triplicate assays) and in BM samples derived from
three healthy donors or from patients with AML. NEs were prepared
using the Nuclear Extract Kit (Active Motif, Carlsbad, CA) according
to the manufacturer’s instructions and dialyzed overnight at 4°C against
dialysis buffer [20 mM Hepes, 10% glycerol, 50 mM KCl, 1 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT (pH 7.5), and protease inhib-
itor] using Slide-A-Lyser MINI Dialysis Unit Plus Float 3500MWCO
(Pierce, Rockford, IL). Protein concentrations were measured by color-
imetric assay (Bio-Rad Assay DC Protein; Bio-Rad). Biotinylated tem-
plates consisting of the hCP and an irrelevant 720-bp DNA fragment
(Bpx) which one derived from the pX region of the HTLV-1 provirus
and served as an internal control for unspecific DNA binding. Biotiny-
lated hCP was amplified by PCR from the pTERTLuc800 plasmid 1
using biotinylated primers BpTERT-F (5′-Biot-AAAAATTTAAATG-
GATCCAAGCTCAGATCC) and BpTERT-F (5′-Biot-AAAATT-
TAAATACAGTACCGGAATGCCAAG). The control template
corresponded to a PCR-generated fragment of the HTLV-1 provirus
pX region with BpX-F (Biot-AAAAATTTAAATCACCTGTCCAGAG-
CATCAGA) and BpX-R (Biot-AAAAATTTAAATGTGGTAG-
GCCTTGGTTTGAA). PCR conditions were 95°C for 10 minutes,
followed by 30 cycles of 95°C for 1 minute and 58°C for 1 minute per-
formed with 50 pmol of each primer, 250 μM dNTP, 4% DMSO, and
2.5 units of Herculase Hotstart DNA Polymerase (Stratagene, La Jolla,
CA). Amplified products were extracted with phenol/chloroform (1:1)
and ethanol precipitated before DNA affinity precipitation assay.
Streptavidin beads (Dynabeads M-280 Streptavidin; Dynal Biotech-
nologies) were washed twice in Buffer T [10 mM Tris-HCl (pH 7.5),
1mMEDTA, 1MNaCl] and concentrated at 10mg/ml in Buffer Twith
0.003% NP-40, using the magnetic particle concentrator (Dynal
Biotechnologies). Streptavidin beads were incubated with biotinylated
template (20 fmol/μg bead) in Buffer T for 30 minutes at room
temperature with constant agitation and washed three times with
Buffer T. Immobilized templates were blocked 15 minutes at room
temperature in Buffer T to which 60 μg/ml casein (Sigma; C-5890),
5 μg/ml polyvinylpyrrolidone, and 2.5 mM DTT were added. The
beads/DNA complexes were washed four times in transcription buffer
and concentrated to 10 μg/ml in Buffer T. Immobilized templates were
freshly prepared before each experiment. Finally, reaction components
were incubated for 40 minutes at room temperature with 400 μg of
dialyzed NEs in Buffer T to which 2.5 mM DTT, 0.1% NP-40, and
protease inhibitors were added. After washing with Buffer T containing
2.5 mM DTT and 0.05% NP-40, DNA template–specific proteins
were eluted with Laemmli buffer and resolved by 12% SDS-PAGE.
Protein Digestion
Protein bands were manually excised from the gels and transferred
to 96-well microtitration plates. Sample preparation was carried out
automatically (EVO150; Tecan, Crailsheim, Germany). Excised gel
samples were washed several times by incubating in 25 mM
NH4HCO3 for 15 minutes and then in 50% (vol/vol) acetonitrile
containing 25 mM NH4HCO3 for 15 minutes. Gel pieces were then
dehydrated with 100% acetonitrile and incubated with 7% H2O2 for
15 minutes before being washed again with the destaining solutions
described above. Then, 0.15 μg of modified trypsin (Promega;
sequencing grade) in 25 mM NH4HCO3 was added to the dehy-
drated gel spots, depending on protein amount. After a 30-minute
incubation at room temperature, 20 μl of 25 mM NH4HCO3 was
added to gel pieces before incubating overnight at 37°C. Peptides
were then extracted from gel pieces in three 15-minute sequential
extraction steps in 30 μl of 50% acetonitrile, 30 μl of 5% formic
acid, and finally 30 μl of 100% acetonitrile. The pooled supernatants
were then transferred tomicrocentrifuge tubes and dried under vacuum.
Nano-LC–MS/MS Analysis
For nano-LC–MS/MS analysis, the dried extracted peptides were
resuspended in water containing 2.5% acetonitrile and 2.5% tri-
fluoroacetic acid, before being transferred to vials compatible with
nano-LC–MS/MS analysis (CapLC, Waters and ESI-Q-TOF Ultima;
Micromass UK,Manchester, United Kingdom). The method consisted
of a 60-minute gradient at a flow rate of 200 nl/min, using a gradient of
two solvents: A (5% acetonitrile and 0.1% formic acid in water) and B
(80% acetonitrile and 0.08% formic acid in water). The system included
a 300 μm × 5 mm PepMap C18 pre-column to pre-concentrate
peptides and a 75 μm × 150 mm C18 column (Gemini C18 phase
for in-house built columns) used for peptide elution. Spectra were
calibrated by fragmentation of glufibrino-peptide in MS/MS mode.
MS and MS/MS data were acquired and processed automatically using
MassLynx 4.0 software (Waters, Milford, MA). Consecutive searches
against, first, a contaminant database and then against the SwissProt
and TREMBL databases were performed for each sample using Mascot
2.0. Peptide modifications allowed during the search were N -acetyl
(protein), dioxidation (M), oxidation (M), cysteic acid (C), and sulfone
(M). The other parameters were peptide tolerance = 0.4 Da, MS/MS
tolerance = 0.4 Da, and one missed cleavage site by trypsin allowed.
Proteins showing two peptides with a score above 40 were automati-
cally validated using homemade software (IRMa, CEA/DSV/iRTSV/
LEDyP). Each protein identified by only one peptide was checked
manually using standard fragmentation rules (five consecutive y ions,
proline rule, b ions complementary to y ions, major peaks assigned).
IRMa was then able to transform a manually validated Mascot data file
into a result file in Excel format.
Statistics
Associations between categorical variables were analyzed by Fisher
exact tests. The central tendency differences between groups were
compared with the Mann-Whitney or Kruskal-Wallis tests. Non-
parametric linear correlations between characteristics were analyzed
by the Spearman rank test. All P values were two-sided.
Supplementary Results
Figure W1. Validation of the MPP assay. To check the accuracy of
the procedure, we first needed to verify that theMPP assay was able
to detect known hTERT transcription factors. To this end, we trans-
fected HeLa cells with pCR3-USF2a, a pCMV plasmid that encodes
bHLH USF2a, which acts as a heterodimer with USF1 in regulating
hTERT promoter activity [8,9]. NEs were prepared from HeLa cells
transfected with pCR3-USF2a or with the corresponding empty
vector, and MPP was carried out as described in the Materials and
Methods section. For both USF2a-overexpressing cells and control
cells, the protein complexes eluted from the hCP or the BpX control
DNA fragments were purified and subjected to Western blot analy-
sis with antibodies recognizing either USF2a or USF1 isoforms. This
figure shows that pCR3-USF2a transfection allowed the detection of
both USF1 and USF2, whereas no signal was obtained either with
the control lysate or with the BpX control DNA fragment. The MPP
assay thus made it possible to detect known specific hTERT pro-
moter partners that included not only the overexpressed USF2a
product but also one of its cognate endogenous partners, USF1.
We therefore used the samemethod to test whether Tax expression
could modify the hTERT promoter proteome (Figure 1A).
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Figure W2. TSA treatment reduces DEK occupancy on the hTERT
promoter. qChIP analysis of DEK association with the hTERT promoter
was carried out as described in the Materials and Methods section.
Results (means ± SDs) are representative of triplicate experiments.
